IGC Pharma, Inc.
Clinical-stage biotech firm developing AI-driven treatments for Alzheimer's disease.
IGC | US
Overview
Corporate Details
- ISIN(s):
- US45408X3089
- LEI:
- Country:
- United States of America
- Address:
- 10224 FALLS ROAD, 20854 POTOMAC
- Website:
- https://igcpharma.com/
Description
IGC Pharma, Inc. is a clinical-stage biotechnology company focused on developing treatments for Alzheimer's disease. The company leverages artificial intelligence (AI) in its development process. Its lead candidate, IGC-AD1, is being evaluated in a Phase 2 clinical trial for treating agitation in patients with dementia due to Alzheimer's. The company's pipeline also includes TGR-63, a pre-clinical small molecule designed to inhibit amyloid plaque aggregation. Supporting its therapeutic development is MINT-AD, an AI-powered platform for the early detection of Alzheimer's and to improve the understanding of disease progression.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all IGC Pharma, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for IGC Pharma, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for IGC Pharma, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
